相关实验视频
Updated: Feb 23, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
创新的多维定量效益风险模型,用于生物制药工业的研究和开发中有效的决策
Maria E Verdugo1, Fabio A Lievano2, Melvin S Munsaka3
1Scientific Collaborations and New Business Advancement, AbbVie, 1 N Waukegan Rd, North Chicago, IL, 60064, USA. maria.verdugo@abbvie.com.
一种新的定量模型,即多维利益风险综合评估 (MBRIE),在药物开发的早期提供客观的利益风险评估 (BR). 这种工具有助于决策,以改善患者的治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
- 监管科学 监管科学
背景情况:
- 药品益处与风险的平衡对于明智的决策至关重要.
- 结构化利益风险 (BR) 评估框架标准化了评估,并纳入了患者的观点.
- 传统的BR评估是定性性的,通常发生在药物开发的晚期.
研究的目的:
- 引入适用于整个药物开发过程中的利益风险评估的定量模型.
- 为优化发展决策提供更客观的BR信息.
- 促进一个以改善患者结果为重点的协作文化.
主要方法:
- 开发了多维利益风险综合评估 (MBRIE) 定量模型.
- 使用评级级 (1-10) 评估了关键的BR属性.
- 使用图形输出对照标准护理 (SOC) 和发展成功概率 (PODS) 的结果.
主要成果:
- MBRIE模型能够在药物生命周期的早期和整个生命周期中进行结构化,定量化的BR评估.
- 图形输出可视化并比较不同维度的属性排名.
- 该模型支持对发展机会的科学建议.
结论:
- MBRIE模型是药物开发中量化利益风险评估的创新工具.
- 早期和持续的定量BR评估可以优化决策.
- 这种方法促进了合作,以提高患者的治疗结果.
更多相关视频
09:38Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Overview
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.